NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Price, News & Analysis → Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad) Free GTHX Stock Alerts $4.77 -0.21 (-4.22%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.74▼$5.2050-Day Range$3.11▼$4.9852-Week Range$1.08▼$6.14Volume1.40 million shsAverage Volume2.27 million shsMarket Capitalization$249.38 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get G1 Therapeutics alerts: Email Address G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside81.7% Upside$8.67 Price TargetShort InterestBearish5.41% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.61Based on 14 Articles This WeekInsider TradingSelling Shares$151,904 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector272nd out of 925 stocksPharmaceutical Preparations Industry116th out of 430 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about G1 Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.41% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 16.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 2.6 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,904.00 in company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 24.21% of the stock of G1 Therapeutics is held by institutions.Read more about G1 Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.55) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about G1 Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.You can watch it here. About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesMay 9, 2024 | msn.comG1 Therapeutics jumps amid takeover speculationMay 9, 2024 | msn.comWhat's Going On With G1 Therapeutics Stock?May 12, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 6, 2024 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by HC WainwrightMay 6, 2024 | americanbankingnews.comWedbush Comments on G1 Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:GTHX)May 6, 2024 | americanbankingnews.comG1 Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.18) Per Share, HC Wainwright Forecasts (NASDAQ:GTHX)May 4, 2024 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 4, 2024 | americanbankingnews.comG1 Therapeutics' (GTHX) Buy Rating Reiterated at Needham & Company LLCMay 12, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 4, 2024 | americanbankingnews.comHC Wainwright Equities Analysts Lower Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX)May 3, 2024 | finance.yahoo.comG1 Therapeutics First Quarter 2024 Earnings: Revenues DisappointMay 2, 2024 | markets.businessinsider.comOptimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela’s Market ExpansionMay 2, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...May 1, 2024 | finance.yahoo.comQ1 2024 G1 Therapeutics Inc Earnings CallMay 1, 2024 | markets.businessinsider.comEvaluating G1 Therapeutics: Insights From 5 Financial AnalystsMay 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comGTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024May 1, 2024 | msn.comG1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue ProjectionsMay 1, 2024 | globenewswire.comG1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsMay 1, 2024 | globenewswire.comG1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from G1 Therapeutics's earningsApril 30, 2024 | msn.comG1 Therapeutics Q1 2024 Earnings PreviewApril 19, 2024 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To ProfitApril 17, 2024 | finance.yahoo.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 17, 2024 | globenewswire.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 12, 2024 | markets.businessinsider.comBuy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment AppealSee More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/12/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+81.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,970,000.00 Net Margins-36.40% Pretax Margin-32.69% Return on Equity-74.75% Return on Assets-24.25% Debt Debt-to-Equity Ratio1.34 Current Ratio2.94 Quick Ratio2.55 Sales & Book Value Annual Sales$82.51 million Price / Sales3.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book9.00Miscellaneous Outstanding Shares52,280,000Free Float47,978,000Market Cap$249.38 million OptionableOptionable Beta1.71 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer Mr. Terry L. Murdock (Age 64)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsZevra TherapeuticsNASDAQ:ZVRAMerrimack PharmaceuticalsNASDAQ:MACKPuma BiotechnologyNASDAQ:PBYIRenovaroNASDAQ:RENBuniQureNASDAQ:QUREView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 99,900 shares on 5/10/2024Ownership: 3.982%Acadian Asset Management LLCBought 375,354 shares on 5/10/2024Ownership: 0.830%SG Americas Securities LLCBought 13,536 shares on 5/7/2024Ownership: 0.026%Denali Advisors LLCSold 35,700 shares on 4/19/2024Ownership: 0.165%John W V UmsteadSold 6,547 sharesTotal: $19,771.94 ($3.02/share)View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price target for 2024? 4 equities research analysts have issued twelve-month target prices for G1 Therapeutics' shares. Their GTHX share price targets range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.67 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2024? G1 Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, GTHX shares have increased by 56.4% and is now trading at $4.77. View the best growth stocks for 2024 here. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The business earned $14.48 million during the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative trailing twelve-month return on equity of 74.75%. During the same quarter in the prior year, the business posted ($0.53) EPS. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? G1 Therapeutics (GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.98%), Acadian Asset Management LLC (0.83%), Denali Advisors LLC (0.16%), SG Americas Securities LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, John W V Umstead, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTHX) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
